Skip to Main Content

A federal bankruptcy court judge has approved the sale of a rare disease drug to a startup company backed by venture capitalist Peter Thiel, a notable step in one of the latest dramas over access to experimental medicines.

At issue is adrabetadex, which Mallinckrodt (MNKKQ) was studying to combat Niemann-Pick type C, or NPC, a rare progressive genetic disorder that mainly affects children. But the company ended clinical testing earlier this year after studies indicated the drug had no benefit. That was a devastating decision for families because there is currently no treatment for NPC approved for use in the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment